Find in Library

Drug-resistant mutations constitute a significant cause of crizotinib treatment failure for non-small cell lung cancer, which poses a major clinical challenge in the successful treatment of non-small cell lung cancer; therefore, the discovery of the resistance mechanisms of crizotinib is of utmost importance. Understanding the acquired BRAF 600E mutation is essential for designing new effective therapeutic combinations against disease progression.